Long-term estrogen-plus-progestin increased venous thromboembolism and biliary tract surgery in postmenopausal women

January 2003
ACP Journal Club;Jan/Feb2003, Vol. 138 Issue 1, p7
Academic Journal
Focuses on a study that investigated the role of long-term estrogen-plus-progestin in increasing the risk of venous throboembolism and biliary tract surgery in postmenopausal women. Assessment of the clinical characteristics of patients; Patient intervention; Outcome measures.


Related Articles

  • The French ESTHER Study of VTE. Speroff, Leon // OB/GYN Clinical Alert;May2007, Vol. 24 Issue 1, p6 

    The EStrogen and THromboEmbolism Risk (ESTHER) study is a case-control study performed with cases from 8 French hospitals and controls from the general population. The results were as follows: The authors concluded that transdermal estrogen is not associated with an increased risk of VTE, and...

  • Oral Contraceptives and Venous Thromboembolism: Which Are the Safest Preparations Available? Girolami, A.; Spiezia, L.; Rossi, F.; Zanon, E. // Clinical & Applied Thrombosis/Hemostasis;Apr2002, Vol. 8 Issue 2, p157 

    Oral contraceptive therapy is associated with a fourfold increased risk of venous thromboembolism as compared with age-matched non-users. The composition of oral contraceptives has varied considerably during the past two to three decades. The estrogen content (ethinylestradiol) has decreased and...

  • Menopausal Hormone Therapy and the Risk for VTE, AD. Elliott, William T. // Infectious Disease Alert;Dec2012 Pharmacology Watch, p1 

    The article discusses a research study on the risk of venous thromboembolism (VTE) in menopausal hormone therapy (HT) formulations. The study found higher risk of VTE in higher estrogen-progesterone combination therapy compared to estrogen-only formulation. It also notes findings of another...

  • Benefits and Risks of OCPs Beyond Contraception. Zepf, Bill // American Family Physician;5/1/2004, Vol. 69 Issue 9, p2233 

    Focuses on the benefits and risks of oral contraceptive pills (OCP). Guidelines on the use of estrogen-progestin oral contraceptives for women; Association of high estrogen doses with myocardial infarction and ischemic stroke; Risk of venous thromboembolism in patients taking pills with progestins.

  • Conjugated estrogen use increases VT risk.  // Reactions Weekly;5/6/2006, Issue 1100, p3 

    Discusses the results of a study regarding conjugated estrogen use in postmenopausal women without a uterus conducted by the Women's Health Initiative (WHI). Final adjudicated venous thromboembolism (VT) data from the WHI conjugated equine estrogen (CEE) trial of women aged 50 to 79 years who...

  • Progestogens and VTE risk when flying. Power, Jo // Pulse;7/8/2002, Vol. 62 Issue 27, p56 

    Gives advice on whether it is reasonable to offer progestogens to postpone menstruations for someone traveling abroad on a holiday. Association between long-haul air travel and risk of venous thromboembolism (VTE); Correlation between combined oral contraceptive intake and the risk of VTE.

  • NIH Findings: Controversy of Hormone Replacement Therapy. Sztykowski, Tadeusz; Burke, Robert E. // American Acupuncturist;Fall2002, Vol. 28, p16 

    Focuses on the controversy behind the use of combined estrogen and progestin in healthy menopausal women. Examination of the effect of Prempro on the prevention of heart disease; Association of the effects with the risk of breast and colon cancer; Decrease of libido among the menopausal women.

  • Study confirms value of progestin-estrogen combination.  // Mayo Clinic Health Letter;May1996, Vol. 14 Issue 5, p4 

    Presents information from a study on the value of progestin and estrogen. Progestin taken with estrogen offsets the risk of uterine cancer; Uses of estrogen; What progestin is.

  • Estrogen plus progestin increased coronary heart disease and breast cancer events in postmenopausal women. Lowe, Julia // ACP Journal Club;Sep/Oct2002, Vol. 137 Issue 2, p41 

    Presents information on a study that investigated the risks and benefits of estrogen plus progestin in healthy postmenopausal women. Design of the study; Analysis of the incidence of diseases between the placebo-controlled trial versus estrogen plus progestin; Rate of unfavorable and favorable...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics